TAXOL INDUCES CELL DEATH WITH CYTOPLASM VACUOLIZATION IN PARAPTOSIS-LIKE BUT NOT ONCOSIS FASHION IN ASTC-a-1 CELLS

YING-YAO QUAN; CHAOYANG WANG; XIAO-PING WANG; TONG-SHENG CHEN

doi:10.1142/s1793545813500466

[1] N. A. Thornberry, Y. Lazebnik, "Caspases: Enemies within," Science 281, 1312–1316 (1998).

[2] H. M. Mehendale, R. A. Roth, G. A. J. Andolfi, J. E. Klaunig, J. J. Lemasters, L. R. Curtis, "Novel mechanisms in chemically induced hepatotoxicity," FASEB J. 8, 1285–1295 (1994).

[3] G. Kroemer, B. Dallaporta, M. Resche-Rigon, "The mitochondrial death/life regulator in apoptosis and necrosis," Annu. Rev. Physiol. 60, 619–642 (1998).

[4] G. Majno, I. Joris, "Apoptosis, oncosis and necrosis: An overview of cell death," Am. J. Pathol. 146, 3–15 (1995).

[5] P. Weerasinghe, S. Hallock, S. C. Tang, B. Trump, A. Liepins, "Sanguinarine overcomes P-glycoprotein- mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells," Exp. Toxicol. Pathol. 58, 21–30 (2006).

[6] X. Liu, T. Van Vleet, R. G. Schnellmann, "The role of calpain in oncotic cell death," Annu. Rev. Pharmacol. 44, 349–370 (2004).

[7] A. Samali, B. Zhivotovsky, D. Jones, S. Nagata, S. Orrenius, "Apoptosis: Cell death defined by caspase activation," Cell Death Differ. 6, 495–496 (1999).

[8] J. C. Kern, J. P. Kehrer, "Acrolein-induced cell death: A caspase-influenced decision between apoptosis and oncosis/necrosis," Chem.-Biol. Interact. 139, 79–95 (2002).

[9] X. Cao, Y. Zhang, L. Zou, H. Xiao, Y. Chu, X. Chu, "Persistent oxygen-glucose deprivation induces astrocytic death through two different pathways and calpain-mediated proteolysis of cytoskeletal proteins during astrocytic oncosis," Neurosci. Lett. 479, 118–122 (2010).

[10] D. Loo, N. Pryer, P. Young, T. Liang, S. Coberly, K. L. King, K. Kang, P. Roberts, M. Tsao, X. Xu, B. Potts, J. P. Mather, "The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo," Mol. Cancer Ther. 6, 856–865 (2007).

[11] P. X. Petit, S. A. Susin, N. Zamzami, B. Mignotte, G. Kroemer, "Mitochondria and programmed cell death back to the future," FEBS Lett. 396, 7–13 (1996).

[12] T. S. Chen, X. P. Wang, L. Sun, L. X. Wang, D. Xing, M. Mok, "Taxol induces caspase-independent cytoplasmic vacuolization and cell death through endoplasmic reticulum (ER) swelling in ASTC-a-1 cells," Cancer Lett. 270, 164–172 (2008).

[13] Q. R. Sun, T. S. Chen, X. P. Wang, X. B. Wei, "Taxol induces paraptosis independent of both protein synthesis and MAPK pathway," J. Cell Physiol. 222, 421–432 (2010).

[14] C. Y. Wang, T. S. Chen, "Intratumoral injection of taxol in vivo suppresses A549 tumor showing cytoplasmic vacuolization," J. Cell Biochem. 113, 1397–1406 (2012).

[15] W. J. Guo, T. S. Chen, X. P. Wang, R. Chen, "Taxol induces concentration-dependent apoptotic and paraptosis-like cell death in human lung adenocarcinoma (ASTC-a-1) cells," J. X-Ray Sci. Technol. 18, 293–308 (2010).

[16] S. Sperandio, I. de Belle, D. E. Bredesen, "An alternative, nonapoptotic form of programmed cell death," Proc. Natl. Acad. Sci. USA 97, 14376– 14381 (2000).

[17] S. Sperandio, K. Poksay, I. De Belle, M. J. Lafuente, B. Liu, J. Nasir, D. E. Bredesen, "Paraptosis: Mediation by MAP kinases and inhibition by AIP-1/ Alix," Cell Death Differ. 11, 1066–1075 (2004).

[18] P. S. Tang, M. Mura, R. Seth, M. Liu, "Acute lung injury and cell death: How many ways can cells die " Am. J. Physiol.-Lung C 294, L632–L641 (2008).

[19] B. E. Trump, I. K. Berezesky, S. H. Chang, P. C. Phelps, "The pathways of cell death: Oncosis, apoptosis, and necrosis," Toxicol. Pathol. 24, 82–88 (1997).

[20] Y. Eguchi, S. Shimizu, Y. Tsujimoto, "Intracellular ATP levels determine cell death fate by apoptosis or necrosis," Cancer Res. 57, 1835–1840 (1997).

[21] M. Leist, B. Single, A. F. Castoldi, S. Kühnle, P. Nicotera, "Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis," J. Exp. Med. 185, 1481–1486 (1997).

[22] S. Kyoi, H. Otani, A. Hamano, S. Matsuhisa, Y. Akita, H. Fujiwara, R. Hattori, H. Imamura, H. Kamihata, T. Iwasaka, "Dystrophin is a possible end-target of ischemic preconditioning against cardiomyocyte oncosis during the early phase of reperfusion," Cardiovasc. Res. 70, 354–356 (2006).